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Deciphering the roles of LGR6 in WNT and EMT signaling in 
pancreatic cancer 
 
1. Introduction 
 
1.1 Pancreatic cancer 
 
The pancreas is both an endocrine gland and a digestive organ. The endocrine islets 
consist of α- and β-cells with the former producing glucagon and the latter secreting 
insulin for glucose regulation. Other cell types include δ-cells which produce 
somatostatin, ε-cells which generate ghrelin, and γ [or PP]-cells for pancreatic 
polypeptide secretion [1]. The exocrine part contains acinar cells and ductal cells and 
the former produce bicarbonate and digestive enzymes including trypsinogen, lipase 
as well as amylase. The intralobular ducts accumulate the secretions, transport them 
first to the main pancreatic duct and then to the duodenum for digestion and absorption 
of carbohydrate, proteins, and lipids [2]. Besides, stromal components support the 
architecture of the pancreas including pancreatic stellate cells (PSC), inflammatory 
cells, acellular extracellular matrix (ECM) as well as nerves. In case of pancreatic 
cancer, desmoplasia even account for more than 50% of the tumor volume [3].  
 
Pancreatic ductal adenocarcinomas (PDAC) is the most common epithelial malignancy 
of the pancreas with an extremely poor prognosis [4]. Geographically, the incidence 
and mortality are higher in developed countries compared to developing countries as 
shown in Figure 1. It is estimated that 367.000 new pancreatic cancer cases were 
diagnosed worldwide, while 359.000 people died from it in 2015 [5]. Currently, PDAC 
is the fourth most common cause for cancer-related death in developed countries with 




an overall 5-year survival rate of approximately 7% [6] and it is expected to become 
second over the next couple of decades because of an increasing incidence and 
limited treatment improvements [7].  
 
Pancreatic cancer is usually diagnosed at late stages due to nonspecific symptoms as 
well as no sensitive and specific screening techniques or tumor markers [8]. PDAC is 
frequently seen with local invasive growth into nerve and vascular structures. Most 
patients were diagnosed at a rather late stage with only 15-20% of patients being 
eligible for surgery [9]. PDAC is complicated by early recurrence, metastasis, and 
resistance to chemotherapy and radiotherapy [10]. All the characteristics attribute 
PDAC to one of the most aggressive cancer types. 
 
Although notable improvements have been achieved for other malignancies, the 
prognosis of PDAC remains poor. Risk factors include age, a determinant factor for 
pancreatic cancer with a peak incidence in the 7th and 8th decade of patients. Other 
risk factors include smoking, alcohol consumption, chronic pancreatitis, obesity, and 
low physical activity [4]. Besides, mutations in specific genes are associated with 
pancreatic carcinogenesis from intraepithelial neoplastic lesions to invasive carcinoma. 
The most common genes include KRAS of which activating mutations occur in more 
than 90% of cases, while inactivating mutations of CDKN2A, TP53 as well as SMAD4 
are present in 50-80% of tumors [11]. In addition, multiple signaling molecules and 
aberrations contribute to the development of pancreatic cancer by impacting tumor 
cells as well as surrounding stromal cells. Signaling pathways activated by 
transforming growth factor (TGF-β) can regulate cell cycle progression [12], promote 
epithelial to mesenchymal transition (EMT) stimulating a more invasive phenotype [13], 
activate PSCs and induce subsequent PSCs-secreted collagen [14]. HEDGEHOG 
signaling ligand sonic hedgehog (Shh) is overexpressed in pancreatic cancer stem 
cells (CSCs) [15]. CSCs are cancer cells which possess the primary characteristics 
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self-renewal and differentiation, but also capabilities such as tumor recapitulation and 
propagation, therapy resistance, and metastasis formation [16]. The high level of Shh 
inhibits tumor cell apoptosis by phosphatidylinositol 3-kinase (PI3K) signaling 
activation as well as Bcl-2 and Bcl-XL stabilization [17]. Besides, Shh increases 
proliferation potentially by cell cycle regulators cyclin D1 and p21 [17]. HEDGEHOG 
signaling plays a significant role in stroma directly increasing desmoplasia deposition, 
which influences the efficiency of drug delivery, potentially even causing chemo-
resistance [18, 19]. NOTCH signaling is primarily activated during embryogenesis, 
however, it is reactivated in some PDAC cases to promote pancreatic cancer 
pathogenesis [12]. Epidermal growth factor receptor (EGFR) family EGFR signaling 
may also be important in PDAC tumorigenesis.  
 
Likewise, the canonical WNT signaling pathway plays a major role during pancreas 
development [20, 21]. Although aberrant WNT/β-catenin signaling has been implicated 
in tumorigenesis in multiple organs [22-24], it is not commonly seen in PDAC [25, 26]. 
However, researchers have shown that an elevated β-catenin accumulation in some 
pancreatic adenocarcinomas and WNT signaling activation correlates with PDAC 
development [27, 28]. Rather than functioning independently in pancreatic 
carcinogenesis and maintenance, most signaling pathways are cross-linked, 
contributing to pancreatic cancer initiation and progression. 
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         Incidence Age-standardized Rates (ASR) in pancreatic cancer 
 
 
Mortality Age-standardized Rates (ASR) in pancreatic cancer 
Figure 1: Estimated Age-standardized Rates (ASR) of incidence and mortality of 
pancreatic cancer worldwide for both sexes in 2012. North American and Europe are areas 
with highest incidence and mortality ASR, while South-central Asia and middle Africa have the 
lowest incidence and mortality ASR in pancreatic cancerData from GLOBOCAN 2012 (IARC) 
www.globocan.iarc.fr 
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1.2 The WNT signaling pathway 
 
The first mammalian WNT1 gene, also known as Int-1, was identified by Nusse and 
his collogues more than 30 years ago. WNT1 was activated when mouse mammary 
tumor virus (MMTV) integrated its proviral DNA at a specific region of the host genome 
[29]. After years of study, the WNT signaling pathway was found to be highly conserved 
among species [30]. The accurate regulation of WNT signaling is essential for 
embryonic processes as well as tissue homeostasis. WNT signaling mediates cell 
behaviors such as proliferation, differentiation, self-renewal, cell polarity, and 
movement [31, 32]. Considering the essential roles during the life span, alterations in 
WNT signaling are associated with diverse diseases including developmental defects 
and cancer. As early as 1991, the adenomatous polyposis coli (APC) gene was found 
to be involved in familial adenomatous polyposis [33, 34]. Subsequently, additional 
WNT pathway components and the connections with the disease were studied. 
 
The WNT pathway is divided into canonical (β-catenin dependent) and non-canonical 
(β-independent) pathways [35]. The non-canonical WNT signaling is subdivided into a 
planar cell polarity (PCP) pathway and a WNT/Ca2+ pathway. They are activated by c-
Jun-N-terminal kinase (JNK) and calcium (Ca2+), respectively [31, 36-38]. The PCP 
pathway mediates tissue morphogenesis during development process and 
synchronous polarity [39, 40]. The WNT/Ca2+ signaling is essential for developmental 
processes. It is triggered by phospholipase C (PLC), leading to inositol 1,4,5-
triphosphate (IP3) and 1,2 diacylglycerol  DAG formation, which further results in 
elevated intracellular Ca2+ concentration [39-41]. High Ca2+ dose induces the activation	
of protein kinase C (PKC), a calmodulin-dependent protein kinase II (CAMKII) as well 
as the nuclear factor activated T cells (NFAT) [40]. Of all the WNT pathways, the 
canonical pathway is by far the best investigated and understood and is the topic of 
the thesis. 

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1.3 The canonical WNT signal pathway 
 
The WNT/β-catenin pathway controls various processes ranging from embryonic 
development to adult tissue homeostasis. Without the presence of WNT ligands, the 
destruction complex comprised of casein kinase1 (CK1), glycogen synthase kinase 3 
(GSK-3β), AXIN, and adenomatous polyposis coli (APC) labels β-catenin for 
degradation. β-catenin is a key mediator of the WNT/β-catenin pathway. It is 
phosphorylated by CK1 at Ser45, which further facilitates the subsequent 
phosphorylation by GSK-3β at Ser33, Ser37, and Thr41. The phosphorylation leads to 
β-catenin ubiquitination through the β-TrCP/Skp pathway and degradation by the 
proteasome [42, 43] (Figure 2A).  
 
In the presence of WNT ligands, WNT/β-catenin signaling gets activated by WNT 
ligands binding to their co-receptors frizzled (FZD) and LRP5/6, further leading to the 
activation of disheveled (DVL). DVL then removes GSK-3β from the destruction 
complex inactivating the APC/AXIN/GSK-3β/CK1. The inactivation of the destruction 
complex results in the accumulation of β-catenin in the cytoplasm with subsequent 
translocation into the nucleus. Protein kinase A (PKA) can phosphorylate β-catenin at 
Ser675 to induce its accumulation in the nucleus [44]. β-catenin then forms a trimeric 
complex with TCF/LEF (T-cell factor / lymphoid enhancer factor) transcription factors 
to regulate WNT target gene expression [45] (Figure 2B).     
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Figure 2: Schematic illustration of the canonical WNT signaling pathway. (A) In the 
absence of WNT ligands, cytoplasmic β-catenin is targeted for degradation. The destruction 
complex contains two scaffolding proteins (APC and AXIN1/2) and two kinases (CK1 and GSK-
3β). APC and AXIN bind to β-catenin and the kinases sequentially phosphorylate β-catenin at 
its Ser and Thr residues. Phosphorylated β-catenin becomes a substrate of the ubiquitin E3 
ligase β-TrCP and is subsequently degraded in the proteasome. Besides, Groucho proteins act 
as transcriptional repressors to take up the nuclear DNA-binding proteins of the TCF/LEF family. 
(B) With the presence of WNT ligands, canonical WNT signaling is triggered by the interaction 
of secreted WNT proteins with its co-receptor FZD and LRP5 or LRP6. The binding of ligands 
and receptors inhibits the destruction complex leading to β-catenin accumulation in the 
cytoplasm. β-catenin then translocates into the nucleus where it associates with the TCF/LEF 
family and induces WNT target gene expression. 
  
TCF/LEF
FZD
LGR6
LRP5/6
AXIN
APC
CK1
WNT
β-catenin
β-catenin
GSK-3β
RSPO
WNT target gene 
DVL 
B 





1.4 WNT proteins  
 
WNT proteins are a family of secreted paracrine glycoproteins with a molecular weight 
of about 40kDa [46]. It has been discovered that at least 19 human WNT proteins share 
common structural characteristics [31]. WNT3a was the first successful purification of 
a canonical WNT protein [47] and is believed to be implicated in both developmental 
physiological processes and carcinogenesis [48, 49]. Researchers found that lipid-
modification of WNT protein may be necessary for WNT secretion as well as efficient 
WNT signaling [47, 50]. One reason is that one domain of the WNT protein that 
interacts with its FZD receptor contains the palmitoleic acid [51]. Palmitoleic acid 
associates with the FZD extracellular cysteine-rich domain (CRD) for WNT signaling 
transduction. Another reason concerns the requirement of porcupine for WNT protein 
palmitoylation and maturation in the endoplasmic reticulum (ER) [52]. Porcupine is a 
multi-pass transmembrane O-acyltransferase in the ER and a highly conserved 
component in the WNT signal pathway in WNT-producing cells [53]. The loss of 
porcupine leads to the failure of WNT3a translocation from the ER to Golgi [52, 54]. In 
addition, seven-transmembrane WNTless (Wls) protein is essential for further WNT 
protein transportation and secretion [55]. Wls can recognize the specific amino 
residues lipidation, facilitate cellular trafficking as well as its translocation from the 
Golgi to the plasma membrane for secretion [53]. 
 
 
1.5 WNT receptors 
 
1.5.1 Frizzled and LRP5/6 receptors 
 
The binding of WNT proteins to a heterodimeric receptor complex comprised of FZD 
and LRP5/6 is the first step to trigger the WNT signaling cascade [53]. The FZD family 
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was first discovered as receptors to the WNT cascade in 1996 [56, 57]. Until now, 
researchers have found 10 distinct family members (FZD1 to FZD10) [58]. All the FZD 
receptors share a similar structure, a seven-transmembrane domain with an 
extracellular CRD at its N-terminal as a platform for binding ligands [51, 59]. The direct 
association of WNT ligands with the CRD domain fully triggers downstream WNT 
signaling by the recruitment of DVL proteins at the membrane [60-62]. The FZD 
receptors belong to a large family of G protein-coupled receptor (GPCR) [63] and it 
was expected that G-protein is functionally associated with the interaction of a FZD 
receptor and DVL. However, no direct association of heterotrimeric G proteins and 
FZD receptors was observed in WNT signal transduction as shown in typical GPCR 
signaling [64]. Still, it remains to be shown that G-proteins take roles in the activation 
of WNT signaling [64-66].  
 
As FZD could activate both the non-canonical and canonical WNT cascades [61, 67], 
the involvement of co-receptors LRP5/6 determines the activation of the canonical 
WNT signaling only [68]. LRP5/6, a single-pass transmembrane molecule, functions to 
mediate the WNT signal pathway. The signal transduction from extracellular to 
intracellular is achieved by the WNT/FZD/LRP5/6 signalosomes [69-71]. The 
phosphorylation of LRP by kinases CK1 and GSK-3β activate the engagement of LRP6 
to AXIN [72-74]. AXIN is a negative regulator in the WNT signal pathway and is kept 
at a low level in the cells. The more AXIN binds to LRP5/6, the less AXIN participates 
in the β-catenin degradation complex. Thereby, AXIN provides a stoichiometric rather 
than a catalytic mechanism to mediate WNT signal transduction. In addition, protein 
kinase A (PKA), G-protein coupled kinases (Grk5/6) and certain cyclin-dependent 
protein kinases participate to LRP phosphorylation [75].  
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1.5.2 Non-conventional receptors 
 
Besides FZD and LRP, other receptors including ROR2, RYK and PTK7, have been 
identified as WNT ligands binding receptors to mediate WNT signaling. For instance, 
WNT ligands bind to the CRD domain of ROR2 to mediate WNT signaling [76, 77]. 
WNT inhibitory protein-1 (WIF-1) binds to WNT inhibitory factor domain (WIF) to down-
regulate the WNT cascade [78]. However, the exact contribution of alternative 
receptors to the WNT signaling process is still unknown. 
 
 
1.6 Secreted agonists in WNT signaling 
 
In addition to WNT ligands, other proteins may either directly or indirectly activate FZD 
or LRP5/6 receptors, resulting in increased β-catenin stability. For example, Norrin and 
R-spondin (the RSPO protein family, consisting of four members) are two types of 
agonists that regulate the WNT signal pathway through the FZD/LRP complex. Norrin 
acts as a direct ligand to the frizzled4/LRP5 complex. Co-expression of Norrin, 
frizzled4, and LPR5 strongly activated WNT signaling [79].  
 
 
1.7 Secreted extracellular antagonist 
 
WNT activity is regulated extensively by modulators at the receptor-ligand level [80], 
such as frizzled related proteins (sFRPs), WNT inhibitory factor-1 (WIF-1), the Dickkopf 
protein family (DKK). The effect of sFRPs is to inhibit WNT signaling either by binding 
to certain WNT ligands to prevent the association with FZD receptors or by binding to 
FZD receptors to inhibit the formation of functional complexes of WNT/FZD [81-83]. 
WIF-1 is to decrease WNT activity by binding to WNT proteinto block formation of the 





WNT/FZD/LRP5/6 complex [78, 84]. DKK family prevent by association with LRP5/6 
to inhibit WNT/FZD/LRP complex [85, 86]. 
 
 
1.8 R-spondin proteins 
 
The R-spondin (RSPO) proteins are secreted agonists of the canonical WNT signaling 
pathway. They are a recently identified family consisting of 4 secreted cysteine-rich 
proteins. RSPO1 was first discovered in 2001, followed by RSPO2 and RSPO3 in 2004, 
whereas RSPO4 was the last ligand identified in 2006 [87-90]. RSPO homologs are 
only present in vertebrate species, not in invertebrates [91].  
 
1.8.1 RSPO structural features 
 
RSPO belong to the thrombospondin type 1 repeat (TSR-1) superfamily [92]. Human 
mature RSPOs share 40%-60% sequence homology, harboring two cysteine-rich 
Furin-like domains at the N-terminal and a central TSR-1 domain [91, 92]. The former 
domains are also present in growth factor receptors of epidermal growth factor (EGF), 
hepatocyte growth factor (HGF), insulin as well as neurotrophic factor [93]. The 
cysteine residues found in two Furin-like domains are essential and sufficient to 
enhance WNT signaling [89, 91, 94]. Three classes of transmembrane proteins have 
been discovered interacting with RSPO as shown in Figure 3. The TSR-1 domain may 
be used for proteoglycans and/or glycosaminoglycan engagement. One Furin-like 
domain binds to cell surface transmembrane E3 ubiquitin ligases, zinc and ring finger 
3 (ZNRF3) and/or its homologs ring finger 43 (RNF43), and another Furin-like domain 
bind to Leucine-rich repeat containing G protein-coupled receptor 4/5/6 (LGR4/5/6). 
The role of RSPOs to enhance WNT signaling might imply the significance of RSPOs  
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in WNT-dependent developmental processes.  
 
 
Figure 3: The general structure of RSPO and their binding sites. Schematic illustration 
shows the protein domain architecture of RSPO with two cysteine-rich Furin-like domains (left), 
a thrombospondin protein 1 domain and basic amino acids. 
 
 
1.8.2 RSPO functions during embryogenesis 
 
RSPO play different roles in developmental processes. RSPO1 determines the 
phenotypic sex phenotype of human and mice. RSPO1 mutations result in a rare 
syndrome with XX sex reversal, palmoplantar hyperkeratosis and high possibility to 
develop skin carcinoma [95]. Moreover, RSPO1 plays a key role in the development 
of the reproductive system [96, 97]. RSPO2 is necessary for organ development of 
limbs, lungs, and hair follicles. RSPO2 mutations lead to limb and lung defects 
associated with weakened canonical WNT signaling [98-101]. Besides, RSPO2 is 
responsible for hair follicle development in domestic dogs [102]. RSPO3 is involved in 
embryonic vasculogenesis and angiogenesis, with an insufficient penetration of blood 
vessels in RSPO3 knockout animals in placenta [103]. Finally, RSPO4 is involved in 
human nail development [104]. It was found that RSPO4 mutations associated with 
congenital anonychia, a rare autosomal recessive condition with the lack of all 
fingernails and toenails [105] . 
 
 
Furin1 Furin2 Basic domainTSR-1
RNF/
ZNRF LGR456
Syndecan 
type marker





1.8.3 Mechanisms of RSPO-mediated enhancement of WNT signaling 
 
Enhancement of the WNT signal pathway by RSPO proteins was first discovered in 
early frog embryos by Kazanskaya and colleagues [89]. One possible mechanism 
concerns the direct association between the RSPO-LGR and the WNT/FZD/LRP5/6 
complex revealed by mass spectrometric approach [106]. Another possible 
explanation implicates its interaction with the transmembrane E3 ubiquitin ligases 
ZNRF3/RNF43 [107]. ZNRF3/RNF43 are negative feedback regulators in WNT 
signaling [107, 108]. Upon the binding of RSPOs to LGR5, ZNRF3/RNF43 are 
removed from the cell surface, which decreases the ubiquitination of FZD and LRP6 
and subsequently potentiates WNT signaling [107]. Collectively, the recruitment and 
engagement of RSPO to the LGR4/5/6 receptors facilitate the interaction of RSPO with 
ZNRF3/RNF43. This process leads to the elimination of ZNRF3/RNF43, consequently 
keeping the presence of FZD receptors and promoting WNT signaling. 
 
 
1.9 LGR receptors 
 
Studies have uncovered new members of the GPCR superfamily with Leucine-rich 
repeats (LRR) associating with RSPO to potentiate canonical WNT signal pathway. 
Those receptors include LGR4/GPR48 and LGR5/GPR49 which were first discovered 
in 1998, and LGR6 in 2000 [109, 110]. LGR6 shares 54% similarity with LGR5, and 
LGR4 is less similar to its homologs with 46% similarity to LGR5 and 44% similarity to 
LGR6. Secreted WNT agonists RSPO1-4 were identified as endogenous ligands to the 
LGR4/5/6 receptors. The high affinity of LGR4/5/6 receptors to RSPO can strongly 
enhance the WNT/β-catenin signal pathway by increasing phosphorylation of LRP5/6 
and β-catenin stabilization [106, 111]. Thus, LGR4/5/6 receptors are special GPCRs 
that regulate WNT/β-catenin signaling. 
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1.9.1 LGR receptor structures 
 
The LGR family proteins are G-protein coupled receptors and are characterized by a 
large extracellular domain (ECD) with multiple LRR [106, 111]. The LGR family is 
further divided into three main groups (A,B,C) according to the amount of LRR and 
LDLa (low-density lipoprotein receptor class A ) [112]. Type A receptors include LGR1, 
the follicle-stimulating hormone receptor (FSHR), LGR2, the luteinizing hormone 
receptor (LHR), and LGR3, the thyroid-stimulating hormone receptor (TSHR). All type 
A receptors harbor seven to nine LRRs as well as a long Hinge region joining the LRR 
region to the 7TM domain. Type C receptors include LGR7 and LGR8, which have a 
shorter Hinge region and a LDLa motif. The engagement of type A/C receptors and 
ligands leads to G-protein-coupled intracellular cAMP production [113]. The type B 
receptor family of LGR4/5/6 is a unique G-protein coupled 7-transmembrane protein 
with a large ECD containing LRR at the N-terminal LGR protein. It is characterized by 
the presence of 16-18 LRRs within the ectodomain.  
 
 
1.9.2 LGR4/5/6 receptor functions 
 
LGR4 is widely expressed in multiple organs such as cartilage, heart, kidney, adrenal 
gland, reproductive tracts, hair follicles, eyes, and nervous system cells. Thus, its 
appearance is broad, not limited to rare stem cell [101]. LGR4 is essential in 
development, as its ablation in embryos showed embryonic lethality [114]. 
Developmental defects in LGR4 knockout mice displayed in multiple organs. The 
affected tissues are accompanied with impaired ductal branching and elongation as 
well as reduced proliferation of epithelial cells [115]. Moreover, LGR4 potentially 
participates in colon cancer because elevated levels of LGR4 were detected in most  
colon tumors [115].  





LGR5 is considered a WNT target gene. It labels stem cells of tissues with high rates 
of self-renewing, including small intestine and colon [116], stomach [117], and hair 
follicles [118]. LGR5 expression is not restricted the above mentioned tissues, but also 
detected in kidney [119], pancreas [120], liver [121], and the mammary gland [122]. 
Epithelial cells of the small intestine and colon are derived from LGR5+ cells, a finding 
discovered by lineage tracing approaches [116]. Additionally, LGR5+ cells can fully 
differentiate into intestinal [123], stomach [117], and mammary gland organoids [124].  
LGR5 is a gene with increased expression in tumors of colorectal, ovarian and hepatic 
tissues, possibly due to mutational activation of canonical WNT signaling in such 
cancers [125-128].  
 
LGR6 labels multipotent stem cells in multiple organs. In the cochlea, dynamic LGR6 
expression was detected during its developmental process [129]. LGR6 labels rare 
cells in basal and luminal compartments of the mammary gland in mice [130]. Those 
LGR6+ cells expand clonally during puberty and regain proliferative ability during 
pregnancy [130]. LGR6 marks stem cells in both anterior and posterior taste buds of 
the tongue [131]. In the lung, LGR6 labels a rare stem cell population that co-expresses 
integrin α6 and its homologue LGR5 [132]. LGR6 was found to be expressed in certain 
cells of the hair follicle. Interestingly, the transplantation of LGR6+ cells seems to 
generate new follicles as well as new epidermis [107]. Regarding the role of LGR6 in 
cancer, loss-of-function mutation of LGR6 in colorectal cancer leads to a failure in 
binding RSPOs with subsequently reduced WNT enhancement [133]. LGR6 mutations 
are involved in tumor development in mammary glands by inducing luminal cell 
expansion [130]. A study showed that the LGR6 promoter is hypermethylated in around 
20% of sporadic colorectal cancers [134]. So far, LGR6 is considered to be a marker 
of adult stem cells and a potential marker for CSCs [108]. LGR6, together with LGR4 
and LGR5, is an are amplifier of WNT signaling and is involved in stem cell maintaining.  
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1.10 Epithelial-mesenchymal transition (EMT) and WNT signaling 
 
Epithelial–mesenchymal transition (EMT) is a process by which epithelial cells 
transdifferentiate into mesenchymal cells. The reverse process was named 
mesenchymal–epithelial transition (MET). It is regulated by transcription factors, 
including zinc finger E-box-binding homeobox 1 (ZEB1), SNAIL family, SNAIL1 and 
SNAIL2, and basic helix–loop–helix (bHLH) family member TWIST [135-138]. During 
the process, epithelial cells undergo a morphological change by losing tight junctions 
and polarity to mesenchymal phenotype characterized by spindle-shaped phenotype, 
less cell adhesion and increased motility [139, 140]. EMT is detected by the expression 
of vimentin and neural cadherin (N-cadherin), as well as the repression of epithelial 
cadherin (E-cadherin) [141, 142]. EMT plays important roles in development processes 
fundamental to various steps of embryogenesis and it is reactivated in cases of wound 
healing, fibrosis, and cancer progression [139, 143, 144]. Moreover, EMT is involved 
in cancer stemness generation by enabling dedifferentiation processes of non-CSCs 
into CSCs. The plasticity of EMT endows cancer cells with the ability to switch between 
the mesenchymal CSCs phenotype and its more differentiated epithelial phenotype 
[145]. Moreover, EMT induction facilitates CSCs dissociating from the primary site and 
colonizing as a secondary tumor through the reverse process of MET [146-148]. 
Therefore, EMT is a critical mechanism during cancer progression and novel 
therapeutic approaches are of interest to confine cancer cells to the site of the primary 
tumor in order to prevent metastatic spread.  
 
WNT signaling is involved in EMT, because β-catenin also plays a role in adherence 
junctions. In this dual role, β-catenin acts on the one hand as a key effector in canonical 
WNT signaling and on the other hand, with E-cadherin and α-catenin to mediate cell 
adhesion [149, 150]. Of note, E-cadherin is a negative regulator of WNT signaling by 
recruiting β-catenin to adherent junctions. The loss of E-cadherin leads to 
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accumulation of β-catenin in the nucleus, activating WNT signaling [151-153]. Upon 
high WNT activity, the direct activation of SNAIL2 or indirect activation of ZEB1 can 
induce EMT, suggesting a feedforward loop of dedifferentiation of cancer cells.  
 
 
1.11 WNT signaling and disease 
 
Studies initially focused on the role of WNT signaling in the regulation of cellular 
proliferation, differentiation, and stem cell maintenance. As shown above, WNT 
signaling overlaps between developmental and oncological processes. Therefore, 
research shifted to the role of WNT signaling in disease. APC gene mutations were 
discovered in case of family adenomatous polyposis, as the loss of APC function leads 
to inappropriate β-catenin accumulation. In that case, additional mutations such as 
KRAS and TP53 would lead to progression of adenomateous polyps to malignancy 
[154].  
 
Besides, aberrant WNT activation has been implicated in PDAC progression and the 
maintenance of CSCs [27, 155]. In analysis of 136 human PDAC tissues, nuclear or 
cytoplasmic accumulation of β-catenin was detected in the majority of PDAC samples 
[28]. Moreover, WNT signaling is supposed to play roles in pancreatic carcinogenesis 
as levels of cytoplasmic and nuclear β-catenin expression associate with the grade of 
PanIN and invasive PDAC [156]. Ilmer and colleagues found rare PDAC cell 
subpopulations with high intrinsic WNT activity that possessed properties of CSCs. 
RSPO2 is capable to enhance WNT signaling, attributing cells with cancer stemness 
traits [157]. Specific traits of CSCs include chemo-resistance, EMT and remote 
metastatic potential [158]. Research demonstrated that altered WNT signaling 
correlated with poor prognosis in PDAC patients, indicating that WNT signaling is a 
predictor of patients outcome and may serve as potential therapeutic targets [159]. 
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1.12 Aim of the study 
 
As explained above, LGR6 is a receptor of RSPO thereby potentially enhancing 
canonical WNT signaling activity. LGR6 is known to mark stem cells of taste buds, lung, 
skin as well as rare mammary gland cells. As its homolog LGR5 was proved to be a 
WNT target gene, this study aims to decipher the role of LGR6 in WNT signaling, apart 
from functions as a receptor of RSPO in PDAC. Considering the overlap between WNT 
signaling and EMT, we also investigated the potential role of LGR6 in EMT. 
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Consumables 
 
Consumables Source 
6-well plates 
NunclonTM delta surface 
Thermo Fisher Scientific, Roskilde, 
Denmark 
12-well plates  
NunclonTM delta surface 
Thermo Fisher Scientific, Roskilde, 
Denmark 
24-well plates  
NunclonTM delta surface 
Thermo Fisher Scientific, Roskilde, 
Denmark 
96-well plates Sarstedt, Nümbrecht, Germany 
5ml pipette Costar, Maine, USA 
10ml pipette Costar, Maine, USA 
25ml pipette Costar, Maine, USA 
1.5ml tips Eppendorf, Hamburg, Germany 
2.0ml tips Eppendorf, Hamburg, Germany 
15ml tube TPP, Trasadingen, Switzerland 
50ml tube Falcon, Reynosa, Mexico 
Blot paper Bio-Rad, California, USA 
Cell culture flask T25 
NunclonTM delta surface 
Thermo Fisher Scientific, Roskilde, 
Denmark 
Cell culture flask T75 
NunclonTM delta surface 
Thermo Fisher Scientific, Roskilde, 
Denmark 
Cell culture flask T125 
NunclonTM delta surface 
Thermo Fisher Scientific, Roskilde, 
Denmark 
Cell scraper TPP, Trasadingen, Switzerland 
FACS tubes Falcon, New York, USA 
Filters 0.25uM Sartorius stedim, Goettingen, Germany 
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Filters 0.45uM Sartorius stedim, Goettingen, Germany 
Film ECL GE healthcare, USA 
Glass cover slips Menzel Gläser 
Thermo Fisher Scientific, Schwerte, 
Germany 
Glass slides 
Marienfeld, Lauda-Köniqshofen, 
Germany 
Hydrophobic pen Dako, Waldbronn, Germany 
Low-attachment 96-well plates Corning, Krailling, Germany 
Nitrocellulose-transfer membrane LI-COR, USA 
Sterile needle BD MicrolanceTM, Heidelberg, Germany 
 
2.1.2 Chemicals 
 
Chemicals   Source     Identifier 
β-Mercaptoethanol 
Sigma-Aldrich, Steinheim, 
Germany 
M6250 
Agarose  
Peqlab Biotechnologie, 
Erlangen, Germany 
35-1020 
Ammonium persulfate 
(APS) 
Serva, Heidelberg, 
Germany 
13376.01 
BSA 
Biomol, Hamburg, 
Germany 
01400.100 
Crystal violet  
Sigma-Aldrich, Steinheim, 
Germany 
C0775 
6X DNA Sample Loading 
Buffer 
Thermo Fisher Scientific, 
Schwerte, Germany 
R0611 
DMEM/ F12 Gibco, New York, USA 11330-032 
DMSO 
Sigma-Aldrich, Karlsruhe, 
Germany 
D2650 
DNA–Ladder standard 
Invitrogen, California, 
USA 
10787-018 
ECLTM Western Blotting 
Detection System 
Amersham Biosciences    RPN2209 
70% Ethanol 
Apotheke GH, Munich, 
Germany 
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>99% Ethanol  
Apotheke GH, Munich, 
Germany 
 
FBS 
Sigma-Aldrich, Missouri, 
USA 
F7524 
Goat serum 
Sigma-Aldrich, Missouri, 
USA 
G6767 
Gemcitabine 
Pharmacy, Munich, 
Germany 
 
Glycin 
Carl Roth, Karlsruhe, 
Germany 
3187.4 
Hoechst 
Invitrogen, California, 
USA 
H3570 
Hydrogen peroxide 30% 
Merck, Darmstadt, 
Germany 
8.22287.1000 
IC Fixation buffer 
eBiosciences  
Invitrogen, California, 
USA 
00-8222-49 
Isopropanol 
Carl Roth, Karlsruhe, 
Germany 
UN1219 
Loading buffer 4x Bio-Rad, California, USA 161-0747 
Methanol 
Merck, Darmstadt, 
Germany 
1.06009.1000 
Milk powder 
Carl Roth, Karlsruhe, 
Germany 
T145.2 
Methyl cellulose 
Sigma-Aldrich, Steinheim, 
USA 
M0387 
Mounting Medium Burlingame, USA 
Vectashield  
H-1000  
NaCl 
Sigma-Aldrich, 
Copenhagen, Denmark 
71380 
PBS  
PAN-Biotech, Munich, 
Germany 
P04-36500 
30% PolyAcrylamid  
Carl Roth, Karlsruhe, 
Germany 
3029.1 
4% PFA 
Pharmacy, Munich, 
Germany 
 
37% PFA 
AppliChem, Darmstadt, 
Germany 
A0823 
Penicillin-Streptomycin Lonza, St. Louis, USA DE17-602E 
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Permeabilization Buffer 
10X 
eBiosciences  
Invitrogen, California, 
USA 
00-8333-56 
Phosphatase inhibitor 
cocktail 
Roche, Mannheim, 
Germany 
04906837001 
Protein standards                              Bio-Rad, California, USA 161-0374 
Protease inhibitor cocktail 
Roche, Mannheim, 
Germany 
05892791001 
RNase-free water Qiagen, Hilden, Germany 129112 
RPMI 1640 Medium                      Gibco, New York, USA 21875-034 
RIPA lysis buffer 10X 
Millipore, Darmstadt, 
Germany 
20-188 
SDS 
Carl Roth, Karlsruhe, 
Germany 
2326.2 
SYBR safe DNA gel stain 
Invitrogen, California, 
USA 
S33102 
TAE buffer 50x 
Serva, Heidelberg, 
Germany 
42549.01 
TEMED  Bio-Rad, California, USA 161-0800 
Tris Base Bio-Rad, California, USA 161-0716 
Triton-X-100 
Sigma-Aldrich, Steinheim, 
Germany 
T8787 
Trypan blue   
Sigma-Aldrich, Steinheim, 
Germany 
T8154 
Trypsin/EDTA Lonza, St. Louis, USA BE17-161E 
Tween 20   
Sigma-Aldrich, 
Heidelberg, Germany 
P1379 
 
 
2.1.3 Antibodies  
                   
Antibodies Source   Identifier 
β-catenin 
Cell signaling Technology 
Frankfurt am Main, Germany Cat#8480 
Phospho-β-catenin 
(Ser675) 
Cell signaling Technology 
Frankfurt am Main, Germany 
Cat#4176 
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GAPDH   
Santa Cruz Biotechnology, 
Texas, USA 
Cat#sc-25778 
E-cadherin   
BD Biosciences, California, 
USA 
Cat#610181 
LGR6   Sigma, Missouri, USA   Cat# HPA008556 
LGR6 APC-conjugated R&D system, Minnesota, USA Cat# FAB8458A-025 
anti-mouse IgG-HRP 
Santa Cruz Biotechnology, 
Texas, USA 
Cat# sc-2005 
anti-rabbit IgG HRP 
Cell signaling Technology 
Frankfurt am Main, Germany 
Cat#7074 
anti-rabbit IgG-FITC 
Santa Cruz Biotechnology, 
Texas, USA 
Cat#sc-2012 
anti-mouse IgG-TR 
Santa Cruz Biotechnology, 
Texas, USA 
Cat#sc-2781 
 
 
2.1.4 Recombinant Proteins and inhibitors 
 
Product Source   Identifier 
B27 Gibco, New York, USA Cat#12587-010 
EGF ImmunoTools, Friesoythe, 
Germany 
Cat#11343406 
FGF-β ImmunoTools, Friesoythe, 
Germany 
Cat#11343623 
IWP2 Selleckchem,Texas, USA Cat#S7085 
RSPO2 Peprotech, New Jersey, USA Cat#120-43 
TGFβ1 ImmunoTools, Friesoythe, 
Germany 
Cat#11343160 
U0126 Cell signaling technology, 
Frankfurt am Main, Germany 
Cat#9903S 
WNT3a R&D system, Minnesota, USA Cat#5036-WN-010 
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2.1.5 Commercial Assays 
 
Product Source   Identifier 
BCA protein Assay kit 
Thermo Fisher 
Scientific, Schwerte, 
Germany 
Cat#23225 
ChIP Assay kit Merck, Darmstadt, 
Germany 
Cat#17-295 
iScript cDNA synthesis kit 
Bio-Rad, California, 
USA 
Cat#1708891 
Lipofectamine RNAiMAX   Invitrogen, California, 
USA 
Cat#13778-100 
RNA isolate kit Peqlab Biotechnologie, 
Erlangen, Germany 
Cat#12-6834-02 
SiPOOLs 
siTOOLs Biotech, 
Munich, Germany  
Sso Fast Eva Green  
Bio-Rad, California, 
USA 
Cat#172-5201 
WST1     
Roche, Mannheim, 
Germany   Cat#05015944001 
 
 
2.1.6 Primers 
 
Primers Source Identifier 
AXIN2 Qiagen, Hilden, Germany Cat#QT00037639 
CDH1 Qiagen, Hilden, Germany Cat#QT00080143 
GAPDH     Qiagen, Hilden, Germany       Cat#QT00079247 
ZEB1 Qiagen, Hilden, Germany Cat#QT00020972 
LGR6    Qiagen, Hilden, Germany    Cat#QT00085827 
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2.1.7 Apparatus 
 
Apparatus Company 
Autoclave  Unisteri, Oberschleißheim, Germany 
AxioCam MRC5 ZEISS, Munich, Germany 
Centrifuge Hettich, Ebersberg, Germany 
Cool Centrifuge Eppendorf, Hamburg, Germany 
Micro centrifuge Labtech, Ebersberg, Germany 
CO2 Incubator Binder, Tuttlingen, Germany 
DNA workstation Uni Equip, Martinsried, Germany 
Drying cabinet 
Thermo Fisher Scientific, Schwerte, 
Germany 
Electronic pH meter 
Knick Elektronische Messgeräte, Berlin, 
Germany 
FACS Fortessa BD Biosciences, Heidelberg, Germany 
4°C Fridge  Siemens, Munich, Germany 
20°C Fridge  Siemens, Munich, Germany 
-80°C Fridge  Siemens, Munich, Germany 
Fluorescence Microscope ZEISS, Munich, Germany 
Ice machine KBS, Mainz, Germany 
Liquid Nitrogen tank MVE Goch, Germany 
Hypercassette 
Biosciences GE Healthcare, Freiburg, 
Germany 
Image Scanner Konica Minolta, Feldkirchen, Germany 
Lamina flow 
Thermo Fisher Scientific, Schwerte, 
Germany 
Microscope Olympus, Hamburg, Germany 
Microwave Oven Siemens, Munich, Germany 
Micro weigh (CHYO) 
Micro Precision Calibration, California, 
USA 
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Mini-trans blot electrophoretic transfer 
cell  
Bio-Rad, California, USA 
Nanodrop 2000 
Thermo Fisher Scientific, Schwerte, 
Germany 
Novex PowerEase 500 Power Supply Invitrogen, California, USA 
Pipette controller  Eppendorf, Hamburg, Germany 
Power Supply Power Pac 300 Bio-Rad, California, USA 
Step one PCR system  
Thermo Fisher Scientific, Schwerte, 
Germany 
Shaker 
Edmund Bühler, Bodelshausen, 
Germany 
Thermocycler  Eppendorf, Hamburg, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
UV illuminator 
LTF Labortechnik, Wasserburg, 
Germany 
VersaMax ELISA Microplate Reader Molecular Devices, California, USA 
Vortex Mixer VF2 (Janke & Kunkel)  IKA, North Carolina, USA 
Water bath Memmert, Schwabach, Germany 
X cell II TM Blot module  Invitrogen, California, USA 
 
 
2.1.8 Software 
 
Software  Company 
Excel  Microsoft 
FACS Diva software BD 
Graphpad 6.0 Prism Version 6.0 
ImageJ Version 1.50i National Institutes of Health,  
Step One software v2.3 Applied Biosystems 
ZEN software Version 2.0 Carl Zeiss 
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2.1.9 Buffers and Solutions 
 
Agarose gel electrophoresis 
 
1xTAE Buffer 
50x TAE buffer 20ml  
H2O 980ml 
 
Western Blot 
 
12% Separating Gel 
H2O 4,3ml   
1.5M Tris pH8.8   2,5ml 
30% PolyAcrylamid   3ml  
10% SDS  100µl  
10% APS  100µl   
TEMED 5µl  
           
Stacking Gel 
H2O 2,3ml  
1M Tris pH6,8   380µl 
PolyAcrylamid   380µl 
10% SDS   30µl 
10% APS  30µl 
TEMED 5µl   
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10xRunning Buffer    
Tris Base  30g   
Glycin 144g 
SDS 10g 
H2O 1L 
 
1xRunning Buffer 
10x Running buffer 100ml  
H2O 900ml 
 
10x Transfer Buffer   
Tris Base  30g  
Glycin 144g 
H2O 1L 
 
1x Transfer Buffer  
10x Transfer Buffer 100ml  
Methanol 100ml 
H2O 800ml 
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10xTBS 
Tris Base 24g   
NaCl  80g 
H2O  1L 
PH 7,6 
 
1xTBS-T 
10xTBS 100ml  
H2O 900ml 
Tween 1ml  
 
1x Stripping Buffer     
Glycin 15g   
H2O 1L 
Tween 500µl 
PH 2.5  
        
Blocking Buffer     
Milk 5% w/v   
 In TBST  
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Protein lysis Buffer 
RIPA buffer 100ml 
Phospho Stop 1 Table 
Protease Inhibitor 1 Table  
 
1M Tris-HCl  
Tris-base 12.12g 
H2O 200ml 
PH 6.8 
1.5M Tris-HCl  
Tris-base 36.34g 
H2O 200ml 
PH 8.8 
 
Loading buffer 
4xloading buffer 900ul 
β-Mercaptoethanol 100ul 
 
10%SDS 
SDS 10g 
H2O 100ml 
 
10%APS 
APS 10g 
H2O 100ml 
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Immunofluorescence staining 
 
Peroxidase Block 
Methanol 16.7ml 
H2O2 0.5ml 
H2O 3.8ml 
 
Colony formation assay 
 
0.5% Crystal violet solution 
Crystal violet 0.5g 
Methanol 20ml 
H2O 80ml 
 
 
2.2 Methods 
 
2.2.1 Cell culture 
 
Human pancreatic cancer cell lines AsPC-1, BxPC-3, Capan-2, Miapaca-2, Panc-1 
were purchased from ATCC. Cells were cultured in RPMI1640, supplemented with 10% 
FBS and 1% penicillin/streptomycin. All cells were kept at a humidified atmosphere of 
5% CO2 at 37°C. Cells were maintained as a monolayer, and passaged with trypsin 
when 80% confluence was reached. All cells were routinely tested for mycoplasma 
according to internal SOPs every four months and authenticated commercially by IDEX 
BioResearch once a year (Ludwigsburg, Germany). 
 
 




2.2.2 Gemcitabine-resistance cells Culture 
 
Gemcitabine resistant cells (GR cells) were obtained by culturing pancreatic cancer 
cell lines in medium with increasing concentration of gemcitabine. The GR cells were 
firstly cultured in medium with 5ng/ml gemcitabine, the medium was changed every 3 
days. Cells were passaged once reached to 80% confluence and subsequently 
exposed to a relatively higher concentration of gemcitabine. The process was repeated 
until resistance population was selected. Each GR cell lines were cultured for more 
than 6 months. 
 
 
2.2.3 GSEA 
 
Gene set enrichment analysis (GSEA) was performed following the guidelines 
published at the Broad Institute web pages (http://www.broadinstitute.org/gsea 
/index.jsp). Gene sets were collected from Molecular Signature Database (MSigDB), 
Pancreatic cancer patients were selected from TCGA database PAAD LGR6corr. 
GESA was performed to identify the correlation of selected gene sets and LGR6 
expression in pancreatic cancer patients. Enrichment scores (ES) was calculated by 
walking through the ranked-ordered gene list, When ES>0, it was considered as 
“enriched”, showing positive correlation of selected gene sets in PAAD LGR6corr 
patients. 
 
 
2.2.4 RNA extraction, reverse transcription and qPCR 
 
2.2.4.1 RNA isolation 
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Cells were cultured in 12-well plates with or without stimulations. Total RNA from 
cultured cells was extracted using RNA isolate kit according to manufacturer´s 
instructions. Culture medium was aspirated off and cells were washed with PBS shortly. 
After 400ul RNA lysis buffer was added into the plates, cells were scratched to facilitate 
complete lysis. The lysate was collected and transferred into a DNA-removing column 
placed on a 2.0ml collection tube. The lysate was then centrifuged for 1 min at 1200 x 
g at room temperature to get flow-through lysate. Afterwards, same amount of 70% 
ethanol was added into lysate and homogenized well by pipetting. The mixture was 
later transferred again into a perfect bind-RNA column and centrifuged at 10000 x g 
for 1 min, the flow-through liquid was discarded. Perfect bind-RNA column containing 
RNA was kept and washed with wash buffer I and wash buffer II respectively to remove 
cellular debris and other contaminants, making sure that only RNA was left in the 
columns. The columns containing RNA was then centrifuged again at 1000 x g for 2 
min to dry completely. The column was then placed into a fresh 1.5 ml tube and 30-
50µl RNase-free water was added directly to the spin column membrane and incubates 
for 3 minutes. Tubes were centrifuged for 1 min at 10000 x g to elute RNA. RNA was 
quantified using Nanodrop 2000, the purity was evaluated by A260/A280 value. RNA 
samples aliquots were stored at -80 °C. 
 
2.2.4.2 cDNA production 
 
cDNA transcription was performed using cDNA synthesis kit following the 
manufacturer´s instructions. Equal amount of RNA (500ng-1µg) was added into a 
RNase-free tube, together with variable volume of RNase-free water calculated 
according to RNA concentration. The total volume of RNA template and RNase-free 
water was made equal to 15µl. Afterwards, 5µl mixture of 5x iScript reaction mix and 
iScript reverse transcriptase was added into the reaction tube (Table 1). RNA samples 
were reverse-transcribed in a thermocycler with the following protocol: Priming, 25 ºC 
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for 5 min, Reverse transcription, 46 ºC for 20 min, RT inactivation,95ºC for 1 min and 
hold at 4°C. cDNA was diluted at 1:10 with RNase-free water before using for RT-PCR. 
 
RNA template variable 
RNase free H2O variable 
5x iScript reaction mix 4µl 
iScript reverse transcriptase 1µl 
Total 20µl 
Table1 Components of cDNA production 
 
2.2.4.3 Real time PCR  
 
PCR was performed using Sso Fast EvaGreen kit, the PCR product was measured 
based on the fluorescent signal which is related to the DNA amount. Master-mix 
containing specific primer, Evagreen supermix, RNase-free H2O, cDNA template was 
prepared for each reaction (Table 2). All the reactions were mixed thoroughly and 
placed in a 96-well plate. The plate was centrifuged at 1,000 rpm for 1 min to make 
sure that all components were at the bottom of the plate. Afterwards, the plate was 
moved to amplification process on StepOne™ Real-Time PCR System. The 
amplification processes were as follows: enzyme activation at 95°C for 30 sec, 40 
cycles of denaturation at 95°C for 5 sec and annealing at 60°C for 20 sec, followed by 
melt curve from 65-95°C. Each sample was performed in duplicate and a negative 
control with sterile RNase free H2O was used instead of template DNA. Housekeeping 
gene GAPDH was used to normalize the variation of cDNA. The change of RNA 
expression was calculated by 2-ΔCt=2-(Ct gene of interest – Ct internal control).  
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Primer 1µl 
cDNA template 2µl 
Evagreen supermix 10µl 
RNase free H2O 7µl  
Table 2. Master-mix of Eva Green-qPCR 
 
 
2.2.5 Agarose Gel Electrophoresis 
 
1.5 g of agarose powder was measured and mixed with 100 mL 1xTAE buffer. The 
mixture was then melted in a microwave for about 5 min until the agarose completely 
dissolved. Agarose solution was cooled down to about 70°C and 10µl SYBR dye was 
added and mixed. Melted agarose solution was poured into the casting tray and the 
combs were placed in the gel casting tray to wait until it is solid. Once solidified, 
agarose gel was placed into the electrophoresis chamber filled with 1xTAE buffer. 
Combs were carefully removed; DNA ladder standard and samples were carefully 
loaded. The running process is 100V, 200mA for 1h. When gel is ready, DNA 
fragments were visualized under ultraviolet (UV) light. 
 
 
2.2.6 Western blot and Co-IP 
 
2.2.6.1 Western Bolt 
 
Cells were seeded into 6-well plates with or without stimulation. After incubation, cells 
were washed twice with cold PBS and then lysed with RIPA lysis buffer containing 
protease inhibitor and phosphatase inhibitor cocktails. Cell monolayers were scratched 
with a cell scraper and the lysate was collected into a tube. After incubation on ice for 




20min, the cell extracts were centrifuged at 12000 rpm for 20 min at 4°C to get protein 
lysate. The supernatant containing total protein was removed into a new tube and the 
protein concentration was measured with BCA protein assay kit according to 
manufacturer’s instructions. The protein concentration in samples obtained was 
calculated with reference to BSA standard curve. Samples containing 30ug protein 
were mixed with 4xloading buffer and heated at 95°C for 5 min. The whole protein was 
then separated by 12% SDS-PAGE gel and transferred onto nitrocellulose membranes. 
Later, the membranes were blocked with 5% non-fat milk in TBST for 1h at room 
temperature. Afterwards, membrane was probed with primary antibodies overnight at 
4˚ C, washed with TBST for three times, and then second-antibody incubation for 1h 
at room temperature and washed again. GAPDH was used to verify the amount of 
protein loaded. The membrane was exposed using enhanced chemiluminescence 
(ECL) reaction system. Amersham Hyperfilms were used to detect Chemiluminescent 
signals. The films were scanned and quantified by Image J.  
 
2.2.6.2 Co-IP 
 
1*106 cells were seeded on dishes with or without stimulation. Old medium was 
replaced with 10ml fresh medium supplement with 270ul formaldehyde. After 
incubation for 10min at 37°C, medium was abandoned and dishes were washed twice 
with PBS containing protease inhibitors. Cells were collected into a tube and 
centrifuged at 2000 rpm at 4°C for 4 mins to get cell pellets. Afterwards, cell pellets 
were resuspended with 200ul SDS lysis buffer containing protease inhibitors and 
incubated on ice for 10 min. Next, lysate was sonicated and centrifuged again at 13,000 
rpm at 4°C for 10 min. The supernatant was removed into a new tube and then diluted 
with dilution buffer at 1:10. Subsequently, 2ml of diluted supernatant with 75ul Salmon 
Sperm DNA/Protein A Agarose-50% slurry incubated for 30 min at 4°C on a shaker. 
The mixture was centrifuged again and supernatant was removed into a new tube. 
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Primary antibody was added into the supernatant and incubated at 4°C overnight. 
Afterwards, 60ul of salmon sperm DNA/Protein A Agarose was added and incubated 
at 4°C on a shaker for 1h. The mixture was centrifuged again gently to get pellets. 
Then, pellets were washed with low salt immune complex wash buffer, high salt 
immune complex wash buffer and LiCl immune wash buffer at 4°C on a shake 
respectively. Pellets were washed again with TE buffer at room temperature for twice. 
After centrifugation, the complex pellets were resuspended at 50ul TE buffer, and then 
1x loading buffer was added, mixed and heated at 95°C for 10min. At last, samples 
were collected for subsequent Western Blot. 
 
 
2.2.7 Sphere-formation assay 
 
Stimulated or transfected cells were digested and resuspended as signal cell 
suspension. After counting and calculation, 1000 cells in 100μl were resuspended in 
CSC medium. The CSC medium was supplemented with 1XB27, 1% 
penicillin/streptomycin, recombinant human epidermal growth factor (EGF) 10ng/ml 
and recombinant human fibroblast growth factor (FGF) 20ng/ml in DMEM/F12. Besides, 
1% methylcellulose was added into medium to prevent cell-cell aggregation. Cells were 
seeded slowly into low attachment 96-well plates to avoid bubbles. Medium was 
changed every 3-4 days with or without stimulators as indicated in the text. After 12-
15 days incubation at 37°C, spheres with more than 50 cells were counted. Images 
were taken by a microscope. 
 
 
2.2.8 Colony-formation assay 
Cells were digested and resuspended as signal cell suspension. 1000 cell were  
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counted and seeded into 6-well plates in complete RPMI1640 medium containing 
stimulators as indicated in the text. The cells were incubated at 37°C, 5% CO2 for 7-
10 days. After incubation, medium was removed and the plates were washed with PBS 
shortly. Afterwards, cells were fixed with 4% PFA for 20 min on a shaker, and washed 
again with PBS. Colonies were stained with 0.5% crystal violet for 10 mins on a shaker, 
and washed again. Clusters with approximately 50 cells or more were considered as a 
colony. 
 
 
2.2.9 siRNA transfection 
 
Cells were seeded into 24-well plates with about 60% confluence in RPMI1640 with 
10% FBS only. After incubation overnight, the old medium was removed, and 400ul 
medium without FBS and P/S was added into plates. Next, LGR6 siPOOL dilution was 
prepared by adding 10μl of 0.15μM LGR6 siPOOL stock solution into 40μl medium, 
negative control was prepared the same way. RNAiMAX dilution was made by pipetting 
1μl RNAiMAX into 49μl medium. Afterwards, either LGR6 siPOOL dilution and 
RNAiMAX dilution, or negative control siRNA dolution and RNAiMAX dilution were 
combined at a ratio of 1:1 and mixed well by pipetting up and down. After incubation 
for 10 min at room temperature to allow transfection complex formation, the mixture 
was added drop-wise into the cell culture plate. The plate was gently shacked and at 
kept in incubator at 37°C, 5% CO2 for 24h or 48h. RNA was isolated 48h after 
transfection. RT-PCR was performed to test the efficiency of transfection. For sphere 
formation assay and colony formation assay, the cells were collected 24h after 
transfection.  
 
 
 




2.2.10 Immunofluorescence staining 
 
2.5*105 cells in 2ml RPMI 1640 media with 10% FBS were seeded on coverslips in 6-
well plates. After stimulation, the slides were washed with PBS shortly and then fixed 
with 4% PFA for 20 mins. It was followed by endogenous peroxidase blocking buffer 
for 10 min on a shaker, and washed with PBST for 5 mins. Afterwards, the cells were 
permeabilized with 0.1% Triton X-100/PBS for 10 min on a shaker, followed by 5 min 
wash with PBST. After blocking with 5% goat serum for 1h at room temperature, the 
cells were incubated with primary antibody at 4°C overnight. Afterwards, the cells were 
washed again and incubated with followed second antibody incubation at room 
temperature for 1h in dark. Nucleus were counterstained with Hoechst (1:10.000 in 
PBS) for 5 min and followed by washing for 5 min. Lastly, slides were mounted in 
Fluorescence Mounting Medium and evaluated by fluorescence microscope with 
specific filter to select individual fluorescence. Images were captured by software 
ZEN2.0. 
 
 
2.2.11 Flow cytometry 
 
Cells with or without stimulation were trypsined, washed and collected into a tube. For 
membrane-bound LGR6 analysis, cells were incubated with human LGR6 APC-
conjugated antibody for 30 min at room temperature and washed with PBS, after 
centrifugation at 500g for 5 min, cell pellet was suspended with PBS again. For 
cytoplasmic LGR6, cells were washed with PBS and centrifuged at 500g for 5 min, the 
supernatant was removed and cells were fixed with 100ul IC fixation buffer for 30 min 
at 4°C, afterwards were washed with 1 ml permeabilization buffer at 500g for 5 min for 
twice. Next, cells were incubated with LGR6 antibody for 30min at room temperature. 
After washing again with permeabilization buffer and PBS respectively, cells were 
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analyzed by BD LSR Fortessa. Negative control was prepared in the same procedures, 
but without antibody incubation. 
 
 
2.2.12 Cell viability assay 
 
Cell viability on gemcitabine was analyzed by WST1 assay. 5000 cells were seeded 
into 96-well plates and attached overnight. Medium was changed with or without 
gemcitabine the following day. Cells were cultured at incubator for 72h at 37°C, 5% 
CO2. The medium was removed and WST1 solution was added according to 
manufacturer´s protocol. 10ul WST1 in 100ul medium was added into each well of 
plates, a negative control was made as a reference. After incubation for 1-2h, OD value 
was quantified by measuring the absorbance at 450nm and references at 620nm on a 
plate reader. The relative cell viability was calculated by Excel.  
 
 
2.2.13 Statistical analysis 
 
Statistical analysis was performed by GraphPad Prism. Data are represented as mean 
± SEM. Comparisons was made by t test. P <0.05 was considered as statistically 
significant. 

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3. Results 
 
3.1 Prediction of LGR6 as a WNT target gene 
 
Gene Set Enrichment Analysis (GSEA) is a powerful software to identify gene 
expression data sharing biological functions or mechanisms in pathways and 
processes. We applied GSEA to uncover the correlation of WNT signaling associated 
gene sets in MSigDB with LGR6 expression in pancreatic cancer patients. Gene sets 
including HERBST_WNT_TARGETS_GENOMICS (64 gene sets), HERBST_WNT_ 
TARGETS_UP (122 gene sets), NUSSE_WNT_TARGETS_IN_INTESTINE_OR 
_COLON_CANCER (35 gene sets) were collected. The most WNT-positive correlated 
gene sets located in high LGR6 expressed samples. Normalized enrichment score and 
False discovery rate were calculated respectively. NES =1.88, FDR =0.0 in 
HERBST_WNT_ TARGETS_GENOMICS; NES = 1.80, FDR =0.0 in HERBST_WNT_ 
TARGET_UP, NES=1.86, FDR =0.0 in NUSSE_WNT_TARGETS_IN_ INTESTINEOR 
_COLON_CANCER (Figure 3.1).  
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Figure 3.1: GSEA enrichment plots of WNT signaling signature positively correlated with 
LGR6 expression in pancreatic cancer. (A) Gene set: HERBST_WNT_TARGETS 
_GENOMICS; (B) Gene set: HERBST_WNT_TARGETS_UP; (C) Gene set: NUSSE_WNT_ 
TARETS_IN_INTESTINE_OR_COLON_CANCER.  
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3.2 Activation of canonical WNT signaling mediates LGR6 expression 
 
As reported before, the stimulation of PDAC cells with RSPO2 resulted in an increased 
WNT activity in high responder cells [157]. To evaluate whether LGR6 expression 
could be altered by WNT signaling, we activated canonical WNT signaling pathway by 
treating Panc1 and Capan2 with human recombinant RSPO2, WNT3a or a 
combination thereof. To confirm whether the WNT signal pathway was activated by 
such stimulation, qPCR analysis for typical WNT target genes (AXIN2) was evaluated. 
No apparent increase was observed upon RSPO2 stimulation alone in both cell lines, 
while WNT3a has limited effect on AXIN2 increase in Panc1 (Figure 3.2.1). The results 
are in line with the fact that exogenous WNT3a is required for functional effects of 
RSPO2 to enhance WNT signaling. 
 
Phosphorylation of β-catenin at Ser675 leads to its accumulation in the nucleus thereby 
enhancing transcriptional WNT activity. Therefore, we performed Western blot to 
analyze the change of phospho-β-catenin-Ser675 upon RSPO2 and/or WNT3a 
stimulation. An increased phospho-β-catenin-Ser675 expression level was observed 
upon RSPO2 and WNT3a stimulation in Panc1, while total β-catenin expression 
remained the same, demonstrating that the differences of phospho-β-catenin-Ser675 is 
not due to total β-catenin up-regulation. However, no apparent changes were observed 
in either RSPO2 or WNT3a simulation of Panc1. Besides, the differences of phospho-
β-catenin-Ser675 were not significant upon stimulation with RSPO2 and/or WNT3a in 
Capan2 (Figure 3.2.2). 
 
The activation of WNT signaling can also be detected by the translocation of β-catenin 
to the nucleus; therefore, we performed immunofluorescence staining to show the 
distribution of β-catenin in response to abovementioned stimuli. We found that β-
catenin was predominantly located at the cell membrane in the untreated group (white 
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arrow) (Figure 3.2.3). After 24h culture with RSPO2, it showed a limited effect on β-
catenin translocation into the nucleus (red arrow). The addition of WNT3a as well as 
RSPO2 led to a significant increase of nuclear β-catenin, implying an activated WNT 
signaling.  
 
Afterwards, LGR6 expression was analyzed by Western Blot to see whether its 
expression correlated with WNT activity. As shown in Figure 3.2.4, LGR6 expression 
was up-regulated upon simultaneous stimulation with RSPO2 and WNT3a in both 
Capan2 and Panc1. These observations gave a hint that WNT/β-catenin activation 
may correlate with high LGR6 expression.  
 
 
Figure 3.2.1: PCR analysis of AXIN2 mRNA levels upon RSPO2 and/or WNT3a stimulation 
in Panc1 and Capan2. No significant changes were detected upon RSPO2 stimulation in both 
cell lines. WNT3a alone increased AXIN2 expression in Panc1. *, P<0.05. The combination of 
RSPO2 and WNT3a had elevated effects on AXIN2 expression in both cell lines. ***, P<0.001.  
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Figure 3.2.2: Western Blot analysis of phospho-β-catenin-Ser675 and total β-cat 
expression after RSPO2 and/or WNT3a stimulation. An increase of phospho-β-catenin 
Ser675 was only seen in Panc1 upon the double stimulation of RSPO2 and WNT3a.*, P<0.05. 
No significant differences were observed in Capan2. GAPDH was used as loading control. 
Quantification evaluation was performed by ImageJ. 
 
total β-cat
 
Panc1
GAPDH

p-β-cat
Ser675
RSPO2
WNT3a
Capan2
            
            
            
            
Panc1 p-β-cat Capan2 p-β-cat




 
                                                         20μm 
Figure 3.2.3: Immunofluorescence staining of β-catenin in Panc1 after stimulation with 
RSPO2 and/or WNT3a. Panc1 cells were cultured with or without RSPO2 
(20ng/ml)/WNT3a(100ng/ml) and stained for β-catenin (green). Nuclei were counterstained with 
DAPI (blue). In the absence of RSPO2 and WNT3a, most β-catenin located on cell membrane. 
In the presence of RSPO2, a limited increase of nuclear β-catenin was seen. While cultured 
with both RSPO2 and WNT3a, considerable increase of nuclear β-catenin was shown. White 
arrows, membrane-bound β-catenin; red arrows, cytoplasmic β-catenin. Bar,20μm. 
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Figure 3.2.4: Western Blot analysis of LGR6 after RSPO2 and/or WNT3a stimulation. An 
increased LGR6 expression was shown both in Panc1 and Capan2 upon RSPO2 and WNT3a 
stimulation. **, P<0.01 in Panc1 and *, P<0.05 in Capan2. No significant difference was seen 
in either RSPO2 or WNT3a stimulation in both cell lines. GAPDH was used as loading control. 
Quantification evaluation was performed by ImageJ. 
 
 
3.3 Inhibition of the WNT signal pathway decreases LGR6 expression 
 
To further investigate the regulatory effects of WNT signaling on LGR6 expression, we 
pharmacologically inhibited the WNT signaling activity by IWP2, a porcupine inhibitor, 
that negatively regulates canonical WNT signaling. As shown in Figure 3.3.1, the 
inhibitory effect was represented by down-regulation of the WNT target gene AXIN2 in 
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Capan2. Such WNT inactivation by IWP2 was also revealed by decreased phospho-
β-catenin-Ser675 levels by Western blot (Figure 3.3.2). Besides, qPCR was carried out 
to investigate whether LGR6 expression in Capan2 changed upon IWP2 treatment. As 
shown in Figure 3.3.3, down-regulation of the WNT signal pathway by IWP2 lead to a 
reduced LGR6 expression on mRNA level in Capan2, but not on protein level (Figure 
3.3.4). These data suggest inhibition of the WNT signaling might lead to a decrease of 
LGR6 expression. 
 
 
Figure 3.3.1: Effect of IWP2 on AXIN2 mRNA expression in Capan2. The cells were cultured 
with 10uM IWP2 for 72h, medium was changed every other day. PCR analysis of AXIN2 
suggests significant decrease in presence of IWP2. ***, P<0.001.  
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Figure 3.3.2: Evaluation ofphospho-β-catenin-Ser675 and total β-cat expression with 
IWP2 treatment in Capan2. The cells were cultured with 10uM IWP2 for 72h. phospho-β-
catenin-Ser675 expression decreased in the presence of IWP2. GAPDH served as loading 
control. Quantification evaluation was performed by ImageJ. 
 
 
 
 
Figure 3.3.3: Effect of IWP2 on LGR6 mRNA expression in Capan2. The cells were cultured 
with 10uM IWP2 for 72h, medium was changed every other day. PCR analysis of LGR6 showed 
significant decrease in presence of IWP2 ***, P<0.001.  
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Figure 3.3.4: Western blot analysis of LGR6 expression upon IWP2 treatment in Capan2. 
The cells were cultured with 10uM IWP2 for 72h, medium was changed every other day. WB 
analysis of LGR6 detected no significant changes in presence of IWP2. GAPDH was used as 
loading control. Quantification evaluation was performed by ImageJ. 
 
 
3.4 Prediction of LGR6 as an indicator of EMT 
 
GSEA was used to investigate whether LGR6 expression correlated with typical 
epithelial/mesenchymal gene signatures. Accordingly, EMT signature gene sets were 
chosen from MSigDB including GOTZMANN_EPITHELIAL_TO_MESENCHYMAL 
_TRANSITION_UP (69 gene sets); JECHLINGER_EPITHELIAL_TO_ 
MESENCHYMAL_TRANSITION_UP (71 gene sets); ANASTASSIOU_CANCER_ 
MESENCHYMAL_TRANSITION_SIGNATURE (64 gene sets); TAUBE_CORE_ 
EPITHELIAL_TO_MESENCHYMAL_TRANSITION_INTERACTOME_GENE-
EXPRESSION_SIGNATURE (91 gene sets). GSEA then suggested that high LGR6 
expression positively correlated with epithelial features as shown in Figure 3.4.1. NES 
= -1.29, FDR=0.05 in JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_ 
TRANSITION_UP; NES =-2.58, FDR=0.0 in TAUBE_CORE_EPITHELIAL_ 
TO_MESENCHYMAL_TRANSITION_INTERACTOME_GENE-EXPRESSION_ 
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SIGNATURE; NES =-1.49, FDR=0.01 in GOTZMANN_EPITHELIAL_TO_ 
MESENCHYMAL_TRANSITION_UP; NES=-2.85, FDR=0.0 in ANASTASSIOU_ 
CANCER_MESENCHYMAL_TRANSITION_SIGNATURE. It might indicate that LGR6 
correlates with a less aggressive form or phenotype of PDAC.  
 
 
Figure3.4.1: GSEA enrichment plots of Epithelial signatures negatively correlated with 
LGR6 expression in pancreatic cancer. (A) Gene set: JECHLINGER_EPITHELIAL_TO 
_MESENCHYMAL_TRANSITION_UP; (B) Gene set: TAUBE_CORE_EPITHELIAL_TO_ 
MESENCHYMAL_TRANSITION_INTERACTOME_GENE-EXPRESSION_SIGNATURE; (C) 
Gene set: GOTZMANN_EPITHELIAL_TO_ MESENCHYMAL_TRANSITION_UP; (D) Gene set: 
ANASTASSIOU_CANCER _MESENCHYMAL_TRANSITION_SIGNATURE.  
A B 
C D 




3.5 LGR6 expression varies in typical epithelial and mesenchymal PDAC cell 
Lines 
 
Pancreatic cancer cell lines were categorized into epithelial and mesenchymal 
phenotypes according to their morphology as well as expression analysis of the 
epithelial marker E-cadherin. PDAC cell lines, such as Capan2 and BxPC3, were 
defined as epithelial due to their strong cell-cell connections and cluster-like 
appearance. In contrast, MiaPaCa2 and Panc1 possess lose cell-cell connections with 
a spindle-like phenotype and were therefore considered mesenchymal (Figure 3.5.1). 
Furthermore, EMT markers were detected using qPCR. CDH1 was highly expressed 
in epithelial cell lines, while the transcription factor ZEB1 was more expressed in 
mesenchymal cell lines (Figure 3.5.2). Western blot analysis also detected 
considerable E-cadherin and β-catenin expression in epithelial PDAC cell lines (Figure 
3.5.3).  
 
To understand LGR6 expression pattern in the above-defined cell lines, we detected 
LGR6 expression on both mRNA and protein level. Notably, higher LGR6 expression 
levels were detected in epithelial cell lines (BxPC3 and Capan2) compared to 
mesenchymal cell lines (MiaPaCa2 and Panc1) by both conventional PCR and RT-
PCR (Figure 3.5.4). In addition, these findings were corroborated by Western blot 
showing similar results (Figure 3.5.5). The differential expression of LGR6 in defined 
epithelial and mesenchymal PDAC cell lines was then analyzed by 
immunofluorescence staining. Strong LGR6 signals can be seen on the cell membrane 
in the epithelial cell lines BxPC3 and Capan2, compared to cytoplasmic LGR6 staining 
in the mesenchymal cell line MiaPaCa2. LGR6 was not detectable in Panc1 (Figure 
3.5.6). Distinct distribution pattern of LGR6 in such cell lines suggest LGR6 could 
correlate with the phenotype of PDAC cell lines. 
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Figure 3.5.1: Morphology of defined epithelial and mesenchymal PDAC cell lines. BxPC3 
and Capan2 have strong cell-cell connection, while MiaPaCa2 and Panc1 are spindle like cells 
with less cell-cell adhesions. Bar,50μm. 
 
 
 
Figure 3.5.2: Evaluation of CDH1 and ZEB1 in PDAC cell lines. qPCR was used to assess 
EMT markers. Epithelial PDAC cell lines BxPC3 and Capan2 have higher CDH1 and lower 
ZEB1 expression levels, while mesenchymal cells express more ZEB1 and less CDH1. 
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Figure 3.5.3: E-cadherin and β-catenin expression in PDAC cell lines. Western blot 
analysis showed higher expression of E-cadherin and β-catenin compared to mesenchymal 
ones. GAPDH was used for loading control. Quantification evaluation was performed by ImageJ. 
 
 
 
Figure 3.5.4: Evaluation of LGR6 mRNA expression in PDAC cell lines by PCR. (A) LGR6 
RNA expression levels of PDAC cell lines were accessed by conventional PCR, molecular 
marker of 100bp and 200bp were set in a 1.5% agarose gel. (B) LGR6 expression was 
measured by qPCR. Compared to BxPC3 and Capan2, LGR6 was expressed to a lower degree 
in MiaPaCa2 and Panc1. 
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Figure 3.5.5: Western blot analysis of LGR6 expression in PDAC cell lines. LGR6 was 
highly expressed in BxPC3 and Capan2 compared to MiaPaCa2 and Panc1. GAPDH served 
as loading control. Quantification evaluation was performed by ImageJ. 
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Figure 3.5.6: Immunofluorescence staining of LGR6 in PDAC cell lines. Representative 
immunofluorescence images showed LGR6 expression pattern in defined epithelial and 
mesenchymal PDAC cell lines. LGR6 was detected by FITC-labeled antibody (green). Nuclei 
were counterstained using DAPI (blue). White arrows, membrane-bound LGR6; red arrows, 
cytoplasmic LGR6. 
 
 
3.6 LGR6 may participate in cell adhesion in epithelial PDAC cell lines 
 
As LGR6 was preferentially expressed in epithelial PDAC cell lines, we next explored 
whether there might be a direct correlation between E-cadherin and LGR6. Therefore, 
Co-IP wasconducted to investigate such a connection. Co-IP is a technique to analyze 
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protein–protein interactions by precipitating intact protein complexes using specific 
antibodies. By targeting a known protein, it is possible to identify the associated 
proteins in a presumed complex. E-cadherin was used as a positive control, because 
of the assembly of E-cadherin/β-catenin in cell junction stabilization. As shown in 
Figure 3.6.1, β-catenin was pulled down by E-cadherin in BxPC3 and Capan2, while 
such connection lacked in Panc1 and MiaPaCa2.  
 
Next, we detected the association of E-cadherin and LGR6 in Capan2 and BxPC3 with 
or without WNT3a stimulation. WNT3a has limited effect on the association of E-
cadherin and β-catenin. However, such connection cannot be seen in MiaPaCa2 and 
Panc1 (Figure 3.6.2). Furthermore, the results were confirmed by immunofluorescence 
staining using E-cadherin (red), LGR6 (green) and β-catenin (green) respectively. We 
observed co-localization of β-catenin, LGR6 and E-cadherin on the cell membrane in 
Capan2 (Figure 3.6.3). Taken together, these results suggest that LGR6 might 
participate in the cell adhesion complex of epithelial PDAC cell lines.  
 
Figure 3.6.1: E-cadherin and β-catenin association. Total cell lysates from BxPC3, Capan2, 
Panc1, and MiaPaCa2 were collected and immunoprecipitation was carried out to show the 
association of E-cadherin and β-catenin. Anti-E-cadherin was used to pull-down E-cadherin 
and associated proteins. 
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Figure 3.6.2: E-cadherin and LGR6 association. Total cell lysates from BxPC3, Capan2, 
Panc1, and MiaPaCa2 with/without WNT3a stimulation were collected. The association of E-
cadherin and β-catenin was used as positive control. Immunoprecipitation showed an existing 
association of E-cadherin and LGR6 in Capan2 and BxPC3. WNT3a has limited (positive) 
effects on this correlation.  
 
  
 
Figure 3.6.3: Co-localization of β-catenin, LGR6 and E-cadherin in Capan2. 
Immunofluorescence staining showed β-catenin (green), E-cadherin (red) and LGR6 (green) 
located in the cell membrane in Capan2. Nuclei were counterstained using DAPI (blue). 
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3.7 EMT induction changes LGR6 expression  
 
We next hypothesized that LGR6 might be associated with EMT based on the 
noteworthy differences of LGR6 expression among defined epithelial and 
mesenchymal PDAC cell lines. EMT was therefore induced to examine the influence 
on LGR6 expression. Upon TGFβ stimulation, Panc1 underwent EMT with the 
morphology of the cells shifting to a more mesenchymal phenotype with spindle-like 
appearance as shown in Figure 3.7.1. The reverse process of EMT, designated as 
MET, was achieved by treating cells with the MEK/ERK inhibitor U0126. Cells become 
tightly adherent compared to normal Panc1 cells. Next, we compared E-cadherin 
expression as an indicator of EMT induction. Western blot showed significant 
differences among the three groups. Thereafter, to investigate how changes in EMT 
could affect LGR6 expression, we used Western blot analysis to evaluate LGR6 
expression in response to EMT induction. LGR6 was up-regulated upon TGFβ 
stimulation. No LGR6 expression differences were observed between the control group 
and the U0126 group as measured. Although no significant differences were seen in 
AsPC1 upon the same procedure, it showed a similar tendency as detected in Panc1 
on both E-cadherin and LGR6 expression (Figure 3.7.2). 
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Figure 3.7.1: Morphological changes of Panc1 after EMT induction. The cells were cultured 
with 10ng/ml TGFβ, or 10uM U0126 for 72h, medium was changed every other day. Red box, 
cells with typical phenotype; black box, magnification of typical phenotype. Bar,100μm. 
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Figure: 3.7.2 Protein analysis of LGR6 and E-cadherin after EMT induction. The cells were 
cultured with 10ng/ml TGFβ, or 10uM U0126 for 72h, medium was changed every other day. 
GAPDH was used as loading control. 
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3.8 LGR6 depletion correlates with reduced cancer stemness  
 
To explore the functional role of LGR6 on cancer cell stemness, we knocked down 
LGR6 by siRNA transfection in Capan2. The knock down efficiency was evaluated by 
qPCR, which showed a 90% decrease in mRNA level compared to vector control 
(Figure 3.8.1). Next, we evaluated the consequence of LGR6 silencing on colony 
formation ability. As shown in Figure 3.8.2A, the colonies are smaller in the siLGR6-
transfected group compared to the vector control. Consistent with this, we conducted 
sphere-formation assays, a functional surrogate assay for cancer stemness, which 
showed a significantly decreased effect of LGR6 knock down on the size and numbers 
of spheroids compared with vector control (Figure 3.8.2B). These data suggest that 
LGR6 is associated with cancer cell stemness.  
 
Figure 3.8.1: LGR6 knock down efficiency. Cells were transiently transfected with siRNA or 
vector control for 48h, RNA was collected and qPCR was performed. **, P<0.01. 
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Figure 3.8.2: LGR6 and cancer cell stemness. (A) Colony formation assay of control versus 
LGR6 knock down in Capan2; (B) Sphere formation assay of Capan2 control versus LGR6 
knock down. Quantification of spheroids is shown as normalized to control group. *, P<0.05**, 
P<0.01. Bar, 200μm. 
 
 
3.9 LGR6 expression in gemcitabine-resistant PDAC cells 
 
Gemcitabine is a first-line treatment for pancreatic cancer. Patients usually benefit from 
chemotherapy based on gemcitabine at the beginning, however, many PDACs will 
eventually develop resistance. To understand whether LGR6 expression alters in cells 
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with gemcitabine resistance, we generated gemcitabine-resistant PDAC cells (GR cells) 
by prolonged exposure to gemcitabine. The morphology of GR cells is distinct from 
parental cells. GR cells underwent morphological changes including increased 
pseudopodia formation, reduced cell adhesion, and more elongated, spindle-shaped 
morphologies compared to their parental cells (Figure 3.9.1). The resistance to 
gemcitabine was evaluated by WST1 assay, when cells were exposed to various 
doses of gemcitabine. MiaPaCa2 GR kept a high viability up to 50ug/ml of gemcitabine, 
while MiaPaCa2 viability was inhibited dramatically at 10ug/ml of gemcitabine (Figure 
3.9.2). Besides, the cell viability of Panc1 GR remained at a relatively high state until 
1ug/ml gemcitabine, while it dramatically lowered in parental Panc1 when treated with 
50ng/ml gemcitabine (Figure 3.9.2).  
 
It was reported that the WNT signaling pathway is involved in doxorubicin-resistant 
cells [160]. It is generally believed that there is a higher stem cell subpopulation in GR 
cells, suggesting a higher WNT activity. Therefore, we performed qPCR to detect 
expression of the WNT target gene AXIN2 as an indicator of WNT activity. In line with 
this, AXIN2 expression is higher in MiaPaCa2 GR cells compared to parental cells. 
However, no significant changes were detected between Panc1 and Panc1 GR (Figure 
3.9.3)  
 
Besides, LGR6 expression was measured on mRNA level in GR as well as parental 
cell lines. qPCR showed that LGR6 expression increased in Panc1 GR compared with 
Panc1. However, LGR6 expression in parental and resistant cells in MiaPaCa2 was 
undetectable (Figure 3.9.4). Furthermore, we compared LGR6 protein expression 
between normal cells and GR cells. Consistent with the results above, Western blot 
analysis showed an elevated LGR6 expression in Panc1 GR cell compared with 
parental cells. However, LGR6 was not detected in any experimental setting in 
MiaPaCa2 (Figure 3.9.5).  
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Figure 3.9.1: The morphological changes of GR cells. MiaPaCa2 GR cells changed to 
spindle or small rounded-shaped with less cell contacts compared to MiaPaCa2; while, Panc1 
GR had more pseudopodia (red arrow). Images were taken by phase contrast microscopy. 
Bar,100μm. 
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Figure 3.9.2: Gemcitabine resistance of GR cells compared to their parental cell lines. 
Cells were incubated with increasing dose of gemcitabine for 72h. WST1 assay was used to 
determine the cell viability. **, P<0.01; ***, P<0,001. 
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Figure 3.9.3: PCR analysis of AXIN2 mRNA in normal and GR cells. (A) An elevated AXIN2 
was measured in MiaPaCa2 GR compared to MiaPaCa2. *, P<0.05. (B) No significant changes 
were detected in Panc1 and Panc1 GR cell. 


Figure 3.9.4: PCR analysis of LGR6 mRNA in normal and GR cells. (A) An increased LGR6 
was detected in Panc1 GR, ***, P<0.001. (B) No significant changes were seen in MiaPaCa2 
and MiaPaCa2 GR cell. 
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Figure 3.9.5: LGR6 expression in normal and GR cells. Protein from normal cells, 
gemcitabine-resistant cells were prepared. Increased LGR6 expression was shown in Panc1 
GR, *, P<0.05. No LGR6 was seen in MiaPaCa2 and MiaPaCa2 GR. GAPDH was used as 
loading control. 
 
 
 
 
 
 
 
 






M
ia
2 
G
R
  
  
  GAPDH 
LGR6 



M
ia
2 
  
 
Pa
nc
1 
Pa
nc
1 
G
R
 
LGR6 




3.10 LGR6 expression is a poor prognostic marker in pancreatic cancer 
 
Last, we searched The Human Protein Atlas to examine the correlation of LGR6 
expression with pancreatic cancer clinical prognosis. It showed that high LGR6 RNA 
expression in tissues correlates with poor survival in pancreatic cancer patients (Figure 
3.10). The result supported LGR6 as a marker of poor outcome in pancreatic cancer.  
 
Figure 3.10: Survival analysis of pancreatic cancer patients according to LGR6 
expression. 5-year survival is 21% of high LGR6 expression and 47% of low LGR6 expression 
respectively, cited by The Human Protein Atlas, https://www.proteinatlas.org 
/ENSG00000133067-LGR6/pathology/tissue/pancreatic+cancer#Location.   
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4. Discussion 
 
4.1 LGR6 is a novel WNT target gene in PDAC 
 
The canonical WNT signaling pathway has long been considered to play essential 
roles in organ development as well as oncogenesis in multiple cancers. When 
activated, β-catenin gets released from its destruction complex in the cytosol and 
translocates to the nucleus where it associates with the TCF/LEF family of transcription 
factors to induce canonical WNT target gene transcription. The research of WNT 
signaling target genes has established well-known genes including AXIN2, MYC, cyclin 
D1, and LGR5 [116, 161-165]. Van de Wetering et al. first identified LGR5 as a WNT 
target gene in human colon cancer cell lines harboring WNT-activating mutations [125]. 
LGR5 has been shown to be a receptor of RSPOs and as such is also involved in 
enhancing the canonical WNT pathway [106, 116]. The RSPO family is a group of 
secreted factors that enhance previously activated WNT signaling by binding to the 
receptors LGR4-6. Evaluation of The Cancer Genome Atlas (TCGA) database showed 
that copy numbers of the RSPO2 gene are upregulated in PDAC tissues compared 
with normal pancreas. In line with this, a previous study of Ilmer et al. could show 
higher levels of RSPO2 in cells with high WNT activity as well as in highly tumorigenic 
pancreatic CSCs in KPC mouse models [157].  
 
As a homolog of LGR5, we hypothesized that LGR6 might be a WNT target gene in 
PDAC apart from its role as a receptor of RSPOs to enhance WNT signaling. According 
to open access data from the TCGA, we found that LGR6 positively correlated with 
typical published canonical WNT signal pathway signatures. Our previous study 
showed that WNT signaling could be activated in response to extrinsically added 
recombinant human WNT3a or RSPO2 and even stronger to their combination in 
several pancreatic cancer cell lines. WNT3a is a widely used canonical WNT ligand for 
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stimulation experiments in the field of canonical WNT signaling. RSPO2 is a potent 
agonist that is able to further increase WNT signal pathway activity in the presence of 
WNT ligands [106, 111]. In the present study, we used a similar approach to activate 
WNT signaling by stimulation with RSPO2 and/or WNT3a. The activity was assessed 
indirectly by detection of AXIN2 mRNA and β-catenin protein expression. In Panc1, 
WNT signaling activity was up-regulated in conditions of WNT3a alone as well as 
combined stimulation with RSPO2 and WNT3a. However, analysis of phospho-β-
catenin (Ser675) expression showed that the activation was only present with RSPO2 
and WNT3a in Panc1. IF confirmed this notion by showing that membrane associated 
β-catenin translocated into the nucleus upon WNT3a or WNT3a/RSPO2 stimulation. 
In case of Capan2, the activation was only detectable after stimulation with 
WNT3a/RSPO2 and assessment by AXIN2 mRNA expression. No significant 
differences were observed in Capan2 by phospho-β-catenin (Ser675) evaluation. The 
inconsistency of WNT signaling activity may be due to the different mechanisms of 
AXIN2 and β-catenin to regulate WNT signaling. AXIN2 is a direct target gene of the 
WNT signaling cascade regulating WNT activity by enhancing the phosphorylation and 
degradation of β-catenin [162]. β-catenin in contrast is the key mediator of the WNT 
pathway, which gets released from the destruction complex and enters the nucleus 
where it converts TCF to a transcriptional activator [166, 167]. We then evaluated 
LGR6 expression in activated WNT signaling conditions. It showed that LGR6 was 
upregulated on protein level upon stimulation with WNT3a/RSPO2 in both cell lines.  
 
Baseline WNT signaling activity can be inhibited by IWP2. We decided to use Capan2 
only because of its high intrinsic WNT signaling activity. WNT signaling activity was 
evaluated by expression of AXIN2 and we found a decreased expression in IWP2 
treated samples. Endogenous LGR6 mRNA expression was downregulated upon 
WNT pathway inactivation, whereas protein analysis did not show the same tendency 
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at the same time point, presumably because protein stability was too high in order to 
be able to detect changes on protein level.   
 
In conclusion, we were able to show that LGR6 expression changed according to WNT 
signaling activity leading to the assumption that the LGR6 gene itself may be a direct 
target of the WNT signaling pathway in pancreatic cancer cells. The regulation of LGR6 
may therefore constitute a critical part of a positive feedback loop for WNT signaling 
activity.   
 
4.2 LGR6 participates in cell adhesion and EMT in PDAC 
 
Previous research showed that either overexpression or knockout of LGR5 led to 
strong changes in cytoskeletal structures and cell adhesion in some colon and liver 
cancer cell lines without endogenous or exogenous RSPO stimulation [168, 169]. For 
instance, one study showed that LGR5 silenced colorectal cancer cells tend to be more 
mesenchymal, while LGR5 overexpression was linked to a more epithelial phenotype 
[168]. Another study concluded that LGR5 overexpression in hepatocellular carcinoma 
cells led to changes from a mesenchymal phenotype to a more aggregated phenotype 
typical for epithelial subtype. Down-regulation of LGR5 shifted cells from an 
aggregated to a spindle-shaped phenotype [169]. Moreover, overexpression of 
endocytosis-impaired LGR5 induced cytoskeleton reorganization independent of 
RSPO activity, a phenotype that was characterized by the presence of elongated 
filopodia [133]. They further showed that LGR5 overexpression modified the actin 
cytoskeleton and enhanced cell-cell adhesion. This novel mechanism explained that 
LGR5 associated with the intracellular scaffold signaling protein IQGAP1, which 
regulates cytoskeletal dynamics and cell adhesion [170]. Concerning LGR6, its 
overexpression in HeLa cells was shown to increase cell migration when treated with 
RSPO1 and WNT3a. Moreover, overactivation of WNT signaling is known to be 
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correlated with increased cell migration [133]. So far, LGR6 functions in cell adhesion 
in PDAC are yet to be defined.  
 
In the present study, we used pancreatic cancer cell lines of different morphological 
appearances to study the role of LGR6 in cell adhesion. For example, Capan2 and 
BxPC3 possess an epithelial phenotype with intensive cell-cell connections, while 
MiaPaCa2 and Panc1 are representatives of the mesenchymal phenotype with 
spindle-shaped morphology and lose cell-cell connections. Therefore, we used 
Capan2 and BxPC3 as epithelial and MiaPaCa2 and Panc1 as mesenchymal PDAC 
cell line representatives. This phenomenon raised our interest to investigate how LGR6 
was distributed in these cell lines. In order to investigate a potential correlation, we 
used Gene Set Enrichment Analysis (GSEA) and found that LGR6 inversely correlated 
with EMT signatures in PDAC. Subsequently, we used different approaches (PCR, WB 
or IF) to look at the LGR6 expression pattern in the above-mentioned four PDAC cell 
lines. Interestingly, LGR6 is preferentially highly expressed in the epithelial cell lines 
Capan2 and BxPC3, whereas the mesenchymal cell lines MiaPaCa2 and Panc1 
harbored much lower LGR6 expression levels. Furthermore, IF was used to detect 
intracellular distribution patterns of LGR6 and showed that LGR6 was mostly located 
on the cell membrane in epithelial cell lines, while less or no expression was detected 
in mesenchymal cell lines. This led to the assumption that LGR6 expression might be 
associated with cell adhesion and EMT processes.  
 
To gain further insights into the role of LGR6 in EMT, we induced EMT and MET 
processes in AsPC1 and Panc1 by stimulation with TGFβ and U0126, respectively. 
Successful EMT induction was achieved according to the morphological change to a 
more spindle-shaped morphology with decreased E-cadherin expression in Panc1. 
MET induction by U0126 changed the morphology of Panc1 to an epithelial phenotype 
with increased E-cadherin expression. According to our hypothesis, WB analysis 
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detected upregulated LGR6 expression upon EMT induction. To study the mechanism 
in more detail, Co-IP was performed using E-cadherin as a specific target protein 
because of its association with β-catenin in cell junction stability. β-catenin was pulled 
down by E-cadherin in the epithelial PDAC cell lines BxPC3 and Capan2. Interestingly, 
LGR6 was also pulled down by E-cadherin, which might indicate that LGR6 constitutes 
a part of the cell adhesion complex directly or indirectly with E-cadherin in epithelial 
PDAC cell lines. Afterwards, we stimulated PDAC cell lines with WNT3a to investigate 
whether the WNT signaling can affect LGR6-associated cell adhesion. However, the 
addition of WNT3a had no significant effects, indicating the irrelevance of WNT 
signaling in regulating such a process. In summary, we could show that LGR6 might 
play a role in EMT/MET processes as well as cell attachment activities in PDAC. 
However, the exact mechanisms will require further investigation.   
 
 
4.3 LGR6 is involved in cancer stemness in PDAC 
 
Cancer stem cells are believed to initiate and maintain the tumor and to be involved in 
their metastasis and chemo-resistance. The properties of self-renewal and 
differentiation have been proposed to be the defining criteria for CSCs. CSCs have 
been studied in multiple solid neoplasms, including breast cancer, prostate cancer, 
colon cancer [171 ] as well as pancreatic cancer [172, 173]. LGR5 was identified as an 
adult stem cells marker in tissues, including intestine, liver, skin, stomach, and ovarian 
epithelium [174, 175]. Recently, LGR5 has been shown to define pancreatic CSCs 
[176] and to be co-expressed with other CSC markers [177]. Regarding LGR6, 
experiments revealed that LGR6+ cells can contribute to the recovery of all skin 
compartments, including hair follicles. It is considered to act as a marker of adult stem 
cells in the skin. Additionally, both LGR5+ and LGR6+ stem cell compartments 
contribute to epidermal repair in response to acute wounds [178, 179]. In the present 
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study, we investigated stemness in PDAC by in vitro surrogate assays, such as colony 
formation capacity in 2D and sphere formation capacity in 3D. LGR6 was knocked-
down by siRNA transfection with more than 90% efficiency. The numbers of colonies 
and spheres were smaller in the knock-down group compared with the vector group. 
Therefore, the deletion of LGR6 might have a negative impact on the growth of spheres 
and colonies, hinting towards a potential role of LGR6 in maintaining PDAC stemness.  
Gemcitabine is a standard care of pancreatic cancer [10]. However, patients either 
have intrinsic or rapidly develop gemcitabine-resistance [180]. Research showed that 
gemcitabine resistant (GR) cells are more invasive and possessed increased CSC 
markers suggesting a higher proportion of CSCs [180]. Cells underwent phenotypic 
changes after gemcitabine treatment to a more mesenchymal phenotype with more 
aggressive and invasive properties [180]. In our studies, we developed MiaPaCa2 GR 
and Panc1 GR cells by culturing them with increasing doses of gemcitabine for at least 
6 months. The resistance was assessed by WST1 assays, which showed a 
significantly higher resistance to gemcitabine. Compared with parental cells, Panc1 
GR had more pseudopodia. Pseudopodia are membrane protrusions of highly dynamic 
actin that extend out from the cell edge. They are considered to participate in cell 
migration and cancer cell invasion [181]. The WNT signal pathway has been reported 
to affect the outcome of gemcitabine therapy [182]. WNT target gene MDR1-encoded 
P-gp leads to chemo-resistance by expulsing anticancer drugs out of cancer cells [183]. 
Additionally, the WNT-associated gene Mre11 functions in repairing DNA double-
strand breaks (DSBs) to influence gemcitabine resistance [184]. In MiaPaCa2 GR cells, 
WNT signaling activity was upregulated as shown by AXIN2 mRNA expression 
analysis. Although not statistically different, there is a tendency that WNT signaling 
activity was higher in Panc1 GR. Moreover, LGR6 was overexpressed in Panc1 GR 
both on mRNA and protein level.  
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Previous studies showed overexpression of LGR5 in malignant pancreatic tissues 
compared with non-neoplastic pancreatic tissue [177]. Moreover, patients with more 
LGR5 positive cells are accompanied with shorter median survival [177]. LGR6 is 
known as a commonly mutated gene in colon cancers using whole-exon sequencing 
[185] and highly expressed in gastric cancer compared with their corresponding normal 
tissue [186]. In vivo studies in mice explored that oncogenic mutation in LGR6 
expressing cells induced luminal cell expansion and tumor development in mammary 
glands [130]. In our study, we found that LGR6 correlates with poor prognosis in PDAC. 
Analyses of The Human Protein Atlas data showed that PDAC patients with high LGR6 
RNA expression was associated with poor survival. In conclusion, we showed that 
LGR6 may be a novel WNT target gene and its expression may be associated with cell 
adhesion. Besides, we uncovered its potential role in cancer stem cell features as well 
as in the prediction of PDAC prognosis. 
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5. Conclusions and future directions 
 
So far, research has reportedly investigated the function of LGR6 in WNT signaling as 
well as in stem cells. In this study, we showed that LGR6 is involved in WNT signaling 
activity of PDAC as LGR6 expression changed accordingly to the activity of WNT 
signaling. The stimulation of the WNT pathway seems to increase LGR6 expression, 
suggesting a positive self-regulatory loop. Furthermore, LGR6 is elevated in epithelial 
PDAC cells and appears to be preferentially membrane-bound, suggesting a role in 
EMT and cell adhesion. Lastly, we uncovered LGR6’s potential role in cancer stem cell 
features and in the prediction of PDAC prognosis.  
 
However, there are a number of limitations to this study. First, we did not generate any 
LGR6-overexpressing PDAC cell lines. Comparison of LGR6+ cells with LGR6- cells 
is a direct way to investigate its role in WNT signaling and other features. Second, the 
gold standard assay to assess WNT signaling activity is the Super TOP/FOP (STF) 
dual-luciferase system. In this study, WNT signaling activity was assessed by AXIN2 
mRNA and (phosphor) β-catenin protein expression. Third, no mouse models were 
implemented to translate the results of in vitro experiments to in vivo conditions. Fourth, 
we did not assess LGR6 expression results of the TCGA in a different cohort of human 
PDAC samples. 
 
Together, we provide compelling evidence that LGR6 might be a novel WNT target 
gene and may participate in cell adhesion and EMT in PDAC. LGR6 may be involved 
in cancer stemness and could be used as a predictive factor of PDAC patients’ 
outcome. Further research is still needed to dissect the exact mechanism of how LGR6 
exerts its effects on the canonical WNT signaling in PDAC as well as EMT under 
physiological as well as pathological conditions of benign and cancerous pancreatic 
cells. 
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6. Summary 
 
The canonical WNT signal pathway has long been considered essential for regulating 
embryonic processes as well as tissue homeostasis. However, alterations in WNT 
signaling are also associated with diverse diseases including developmental defects 
as well as multiple cancers. The R-spondin (RSPO) family is a group of secreted 
factors that enhance previously activated WNT signaling activity by binding to 
LGR4/5/6 (leucine-rich repeat containing G-protein coupled receptors 4/5/6). Of note, 
one of the receptors - LGR5 - is a well-established WNT target gene and (cancer) stem 
cell marker. So far, little evidence exists about the function of LGR6 in PDAC. 
Epithelial–mesenchymal transition (EMT) is a process by which epithelial cells 
transdifferentiate into mesenchymal cells. The overlap between WNT signaling and 
EMT compelled us to investigate the potential role of LGR6 in EMT. 
 
According to open access data from the TCGA, we found that LGR6 positively 
correlated with typical published canonical WNT signal pathway signatures. Hence, we 
further hypothesized that LGR6 could be a novel WNT target gene in PDAC. WNT 
signaling was activated by stimulation with RSPO2 and/or WNT3a, which subsequently 
upregulated LGR6 expression in different PDAC cell lines. Moreover, inhibition of 
baseline WNT signaling activity by IWP2 led to downregulation of endogenous LGR6 
expression. Taken together, we were able to show that LGR6 gene itself may be a 
direct target of the WNT signaling pathway in PDAC cells with LGR6 expression 
changes according to WNT activity.   
 
LGR6 is involved in regulating EMT processes in PDAC. Gene Set Enrichment 
Analysis (GSEA) showed that LGR6 was inversely correlated with EMT signatures in 
PDAC. PDAC cell lines of different morphological appearances were used to assess 
the distribution of LGR6 expression. We found that epithelial cell lines (BxPC3, Capan2) 
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possessed a higher LGR6 expression compared to mesenchymal cell lines (MiaPaCa2, 
Panc1). IF showed that LGR6 was mostly located at the cell membrane in epithelial 
cell lines, while less or no expression was detected in mesenchymal cell lines. 
Furthermore, EMT induction was carried out and LGR6 expression was analyzed. We 
detected upregulated LGR6 expression upon EMT induction in Panc1. Additionally, 
Co-IP showed that LGR6 may constitute a part of the cell adhesion complex in 
epithelial PDAC cell lines. 
 
Cancer stemness in PDAC was assessed by surrogate assays in vitro including colony 
formation capacity in 2D and sphere formation capacity in 3D. We investigated the 
effects of LGR6 knock-down on cancer stemness. The numbers of colonies and 
spheres were smaller in the knock-down group compared with the vector group. Thus, 
we concluded that the deletion of LGR6 might have a negative impact on the growth 
of spheres and colonies. As gemcitabine resistant (GR) cells are more invasive and 
possessed increased CSC markers suggesting a higher proportion of CSC, we 
developed MiaPaCa2 GR and Panc1 GR cells by culturing them with increasing doses 
of gemcitabine for at least six months. LGR6 was detected overexpressed in Panc1 
GR both on mRNA and protein level. In addition, we searched The Human Protein 
Atlas and showed that high LGR6 RNA expression in tissues correlates with poor 
survival in pancreatic cancer patients. This supported our hypothesis that LGR6 could 
serve as a marker of poor outcome in pancreatic cancer. 
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